Nomura Asset Management Co. Ltd. Buys 118,138 Shares of Insulet Corporation $PODD

Nomura Asset Management Co. Ltd. grew its stake in shares of Insulet Corporation (NASDAQ:PODD) by 285.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 159,549 shares of the medical instruments supplier’s stock after buying an additional 118,138 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Insulet were worth $45,350,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Glenmede Investment Management LP boosted its holdings in Insulet by 1.6% during the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock worth $708,000 after buying an additional 35 shares during the last quarter. Curi Capital LLC boosted its holdings in Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after buying an additional 36 shares during the last quarter. WINTON GROUP Ltd boosted its holdings in Insulet by 0.9% during the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock worth $1,261,000 after buying an additional 37 shares during the last quarter. Camarda Financial Advisors LLC boosted its holdings in Insulet by 0.5% during the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock worth $2,304,000 after buying an additional 40 shares during the last quarter. Finally, Larson Financial Group LLC boosted its holdings in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of recent analyst reports. Bank of America reduced their target price on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Citigroup reduced their target price on Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday. Evercore reduced their target price on Insulet from $240.00 to $200.00 in a report on Thursday, May 7th. Sanford C. Bernstein reduced their target price on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Weiss Ratings lowered Insulet from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 15th. Twenty-one research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $252.04.

Insulet Stock Performance

NASDAQ PODD opened at $144.94 on Monday. The firm has a market cap of $10.04 billion, a P/E ratio of 33.71, a P/E/G ratio of 1.14 and a beta of 1.13. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The stock’s 50-day moving average is $183.55 and its 200-day moving average is $244.77. Insulet Corporation has a one year low of $140.63 and a one year high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s revenue was up 33.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts anticipate that Insulet Corporation will post 6.44 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.